Literature DB >> 24910389

Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis.

Yingqiu Xie1, Shenji Liu1, Wenfu Lu1, Qing Yang1, Kieosha D Williams2, Awadh A Binhazim3, Brett S Carver4, Robert J Matusik5, Zhenbang Chen6.   

Abstract

SLUG represses E-cadherin to promote epithelial-mesenchymal transition (EMT) in various cancers. Mechanisms that regulate SLUG/E-cadherin pathway remain poorly understood, especially during tumorigenesis in vivo. Here we report that p19(Arf) (p14(ARF) in human) stabilizes Slug to inhibit E-cadherin in prostate cancer mouse models. Inactivation of p19(Arf) reduces Slug levels, resulting in increased E-cadherin expression and delaying the onset and progression of prostate cancer in Pten/Trp53 double null mice. Mechanistically, p14(ARF) stabilizes SLUG through increased sumoylation at lysine residue 192. Importantly, levels of SLUG and p14(ARF) are positively correlated in human prostate cancer specimens. These data demonstrated that ARF modulates the SLUG/E-cadherin signaling axis for augmenting prostate tumorigenesis in vivo, revealing a novel paradigm where the oncogenic functions of SLUG require ARF to target E-cadherin in prostate cancer. Collectively, our findings further support that ARF has dual tumor suppressive/oncogenic roles in cancers in a context-dependent manner.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mouse model; Prostate cancer; SLUG; SUMO1

Mesh:

Substances:

Year:  2014        PMID: 24910389      PMCID: PMC4198473          DOI: 10.1016/j.molonc.2014.05.006

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  39 in total

1.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

2.  The ARF tumor suppressor can promote the progression of some tumors.

Authors:  Olivier Humbey; Julia Pimkina; Jack T Zilfou; Michal Jarnik; Carmen Dominguez-Brauer; Darren J Burgess; Christine M Eischen; Maureen E Murphy
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

3.  Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses.

Authors:  Delin Chen; Jing Shan; Wei-Guo Zhu; Jun Qin; Wei Gu
Journal:  Nature       Date:  2010-03-07       Impact factor: 49.962

Review 4.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

5.  Ubiquitination of, and sumoylation by, the Arf tumor suppressor.

Authors:  Willem den Besten; Mei-Ling Kuo; Kenji Tago; Richard T Williams; Charles J Sherr
Journal:  Isr Med Assoc J       Date:  2006-04       Impact factor: 0.892

6.  Sumoylation induced by the Arf tumor suppressor: a p53-independent function.

Authors:  Kenji Tago; Susanna Chiocca; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

7.  Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis.

Authors:  Yan-Nian Liu; Ying Liu; Han-Jung Lee; Yung-Hsiang Hsu; Ji-Hshiung Chen
Journal:  Mol Cell Biol       Date:  2008-09-15       Impact factor: 4.272

8.  Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis.

Authors:  Yingqiu Xie; Shenji Liu; Wenfu Lu; Qing Yang; Kieosha D Williams; Awadh A Binhazim; Brett S Carver; Robert J Matusik; Zhenbang Chen
Journal:  Mol Oncol       Date:  2014-05-21       Impact factor: 6.603

9.  SUMO1-dependent modulation of SERCA2a in heart failure.

Authors:  Changwon Kho; Ahyoung Lee; Dongtak Jeong; Jae Gyun Oh; Antoine H Chaanine; Eddy Kizana; Woo Jin Park; Roger J Hajjar
Journal:  Nature       Date:  2011-09-07       Impact factor: 49.962

10.  p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.

Authors:  Chun-Ju Chang; Chi-Hong Chao; Weiya Xia; Jer-Yen Yang; Yan Xiong; Chia-Wei Li; Wen-Hsuan Yu; Sumaiyah K Rehman; Jennifer L Hsu; Heng-Huan Lee; Mo Liu; Chun-Te Chen; Dihua Yu; Mien-Chie Hung
Journal:  Nat Cell Biol       Date:  2011-02-20       Impact factor: 28.824

View more
  29 in total

1.  ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Tomasz B Owczarek; Takashi Kobayashi; Ricardo Ramirez; Lijie Rong; Anna M Puzio-Kuter; Gopa Iyer; Min Yuen Teo; Francisco Sánchez-Vega; Jingqiang Wang; Nikolaus Schultz; Tian Zheng; David B Solit; Hikmat A Al-Ahmadie; Cory Abate-Shen
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

Review 2.  Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives.

Authors:  Mir Mohd Faheem; Nathan D Seligson; Syed Mudabir Ahmad; Reyaz Ur Rasool; Sumit G Gandhi; Madhulika Bhagat; Anindya Goswami
Journal:  Cell Death Discov       Date:  2020-06-15

3.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

4.  Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.

Authors:  Juliane Colditz; Benjamin Rupf; Caroline Maiwald; Aria Baniahmad
Journal:  Mol Cell Biochem       Date:  2016-08-25       Impact factor: 3.396

5.  Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes.

Authors:  Yingqiu Xie; Sanzhar Naizabekov; Zhanlin Chen; Tursonjan Tokay
Journal:  Oncol Lett       Date:  2016-05-26       Impact factor: 2.967

6.  Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis.

Authors:  Yingqiu Xie; Shenji Liu; Wenfu Lu; Qing Yang; Kieosha D Williams; Awadh A Binhazim; Brett S Carver; Robert J Matusik; Zhenbang Chen
Journal:  Mol Oncol       Date:  2014-05-21       Impact factor: 6.603

7.  MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.

Authors:  Raj R Bhanvadia; Calvin VanOpstall; Hannah Brechka; Nimrod S Barashi; Marc Gillard; Erin M McAuley; Juan Manuel Vasquez; Gladell Paner; Wen-Ching Chan; Jorge Andrade; Angelo M De Marzo; Misop Han; Russell Z Szmulewitz; Donald J Vander Griend
Journal:  Clin Cancer Res       Date:  2018-05-01       Impact factor: 12.531

Review 8.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

9.  JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells.

Authors:  Bo Tang; Guangying Qi; Fang Tang; Shengguang Yuan; Zhenran Wang; Xingsi Liang; Bo Li; Shuiping Yu; Jie Liu; Qi Huang; Yangchao Wei; Run Zhai; Biao Lei; Hongping Yu; Xingyuan Jiao; Songqing He
Journal:  Oncotarget       Date:  2015-05-20

Review 10.  Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.

Authors:  Dennis M Timmerman; Tessa L Remmers; Sanne Hillenius; Leendert H J Looijenga
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.